Can skyrizi be used for psoriatic arthritis maintenance?

Can Skyrizi treat psoriatic arthritis after initial symptoms are under control?

Skyrizi (risankizumab-rzaa) is approved for adults with active psoriatic arthritis. Clinical studies show it reduces joint inflammation and prevents further damage when used long-term. Maintenance dosing is typically 150 mg by subcutaneous injection every 12 weeks after the first three loading doses at weeks 0, 4, and 16.

What dosing schedule is used for ongoing psoriatic arthritis control?

After the loading doses, patients receive one injection every three months. This interval was selected because the drug’s half-life supports sustained IL-23 inhibition with quarterly administration. Missed doses should be given as soon as possible, then the schedule resumes every 12 weeks from the new date.

How does Skyrizi compare with other IL-23 or IL-17 inhibitors for psoriatic arthritis?

Skyrizi targets the p19 subunit of IL-23, while drugs such as guselkumab (Tremfya) also block IL-23 and secukinumab (Cosentyx) or ixekizumab (Taltz) block IL-17A. Head-to-head data are limited, but all show similar rates of ACR20 response and skin clearance. Choice often depends on prior treatment failures, dosing convenience, and patient preference for injection frequency.

When does Skyrizi’s patent protection end?

The composition-of-matter patent for risankizumab expires in 2032 in the United States. [1] Biosimilar developers are already studying potential versions, but market entry before patent expiry is unlikely unless litigation or regulatory changes occur.

What side effects do patients most often report during maintenance therapy?

Common reactions include upper respiratory infections, headache, and injection-site reactions. Serious infections and hypersensitivity reactions are rare but require prompt medical attention. Patients should discuss vaccination status with their doctor before starting or continuing long-term use.

[1] https://www.drugpatentwatch.com